JP2019511236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511236A5 JP2019511236A5 JP2018554069A JP2018554069A JP2019511236A5 JP 2019511236 A5 JP2019511236 A5 JP 2019511236A5 JP 2018554069 A JP2018554069 A JP 2018554069A JP 2018554069 A JP2018554069 A JP 2018554069A JP 2019511236 A5 JP2019511236 A5 JP 2019511236A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- car
- nucleic acid
- site
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323623P | 2016-04-15 | 2016-04-15 | |
| US62/323,623 | 2016-04-15 | ||
| US201662323675P | 2016-04-16 | 2016-04-16 | |
| US62/323,675 | 2016-04-16 | ||
| US201762461677P | 2017-02-21 | 2017-02-21 | |
| US62/461,677 | 2017-02-21 | ||
| US201762462243P | 2017-02-22 | 2017-02-22 | |
| US62/462,243 | 2017-02-22 | ||
| PCT/US2017/027601 WO2017180989A2 (en) | 2016-04-15 | 2017-04-14 | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511236A JP2019511236A (ja) | 2019-04-25 |
| JP2019511236A5 true JP2019511236A5 (enExample) | 2020-05-28 |
| JP7058223B2 JP7058223B2 (ja) | 2022-04-21 |
Family
ID=59285314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554069A Active JP7058223B2 (ja) | 2016-04-15 | 2017-04-14 | トランスジェニックｔ細胞及びキメラ抗原受容体ｔ細胞組成物及び関連方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11377637B2 (enExample) |
| EP (3) | EP3443075B1 (enExample) |
| JP (1) | JP7058223B2 (enExample) |
| KR (3) | KR102614675B1 (enExample) |
| CN (1) | CN109790517B (enExample) |
| AU (1) | AU2017250769B2 (enExample) |
| BR (1) | BR112018071199A2 (enExample) |
| ES (2) | ES3039670T3 (enExample) |
| PT (2) | PT4180519T (enExample) |
| SG (1) | SG11201808831TA (enExample) |
| WO (1) | WO2017180989A2 (enExample) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3250680A4 (en) | 2015-01-26 | 2018-12-05 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| JP2018518182A (ja) | 2015-06-17 | 2018-07-12 | ザ ユーエービー リサーチ ファンデーション | ゲノム編集のためのｃｒｉｓｐｒ／ｃａｓ９複合体 |
| AU2016278959A1 (en) * | 2015-06-17 | 2018-01-18 | The Uab Research Foundation | CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage |
| DK3359184T3 (da) | 2015-10-05 | 2020-06-15 | Prec Biosciences Inc | Genetisk modificerede celler, der omfatter et modificeret gen fra konstant alfaregion i human t-cellereceptor |
| DK3359660T3 (en) | 2015-10-05 | 2020-02-17 | Prec Biosciences Inc | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| AU2016349504B2 (en) | 2015-11-04 | 2023-02-09 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| SG11201803145RA (en) | 2015-11-04 | 2018-05-30 | Fate Therapeutics Inc | Methods and compositions for inducing hematopoietic cell differentiation |
| CA3020330A1 (en) * | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
| SG11201808831TA (en) | 2016-04-15 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| US11873511B2 (en) * | 2016-10-19 | 2024-01-16 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| GB2607227B (en) * | 2016-10-27 | 2023-05-10 | Intima Bioscience Inc | Viral methods of T cell therapy |
| CN118370809A (zh) | 2017-04-03 | 2024-07-23 | 百欧恩泰美国公司 | 蛋白质抗原及其用途 |
| WO2018204352A1 (en) | 2017-05-01 | 2018-11-08 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| MX2019015188A (es) | 2017-06-15 | 2020-08-03 | Univ California | Inserciones de adn no virales orientadas. |
| CA3068465A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| US20200216515A1 (en) * | 2017-07-26 | 2020-07-09 | Cellectis | Methods of antigen-dependent chimeric antigen receptor (car) immune cell selection |
| US12570711B2 (en) * | 2017-09-27 | 2026-03-10 | Angeles Therapeutics, Inc. | Platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy |
| JP7101419B2 (ja) | 2017-10-27 | 2022-07-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 内因性ｔ細胞受容体の標的置換 |
| WO2019126186A1 (en) | 2017-12-18 | 2019-06-27 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
| EP3749687A4 (en) * | 2018-02-11 | 2021-12-29 | Memorial Sloan Kettering Cancer Center | Non-hla restricted t cell receptors and uses thereof |
| KR102618231B1 (ko) * | 2018-02-16 | 2023-12-28 | 카이트 파마 인코포레이티드 | 변형된 만능성 줄기 세포, 및 제조 및 사용 방법 |
| US20200224160A1 (en) * | 2018-02-27 | 2020-07-16 | Sorrento Therapeutics, Inc. | Process for dna integration using rna-guided endonucleases |
| AU2019253562B2 (en) * | 2018-04-09 | 2025-11-27 | The Trustees Of The University Of Pennsylvania | Methods and compositions comprising a viral vector for expression of a transgene and an effector |
| US11786554B2 (en) | 2018-04-12 | 2023-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene |
| WO2019204397A1 (en) * | 2018-04-17 | 2019-10-24 | Wake Forest University Health Sciences | Methods and compositions for th9 cell mediated cancer treatment |
| US20210207174A1 (en) * | 2018-05-25 | 2021-07-08 | The Regents Of The University Of California | Genetic engineering of endogenous proteins |
| US20200054675A1 (en) | 2018-06-01 | 2020-02-20 | Washington University | Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy |
| EP3810182A4 (en) | 2018-06-19 | 2022-08-24 | BioNTech US Inc. | Neoantigens and uses thereof |
| US12359169B2 (en) | 2018-06-20 | 2025-07-15 | Shanghai Longyao Biotechnology Inc., Ltd. | Universal CAR-T cell and preparation method and use thereof |
| CN110616188B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种通用型car-t细胞及其制备方法和应用 |
| JP2021529559A (ja) * | 2018-07-03 | 2021-11-04 | ソティオ，リミティド ライアビリティ カンパニー | グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 |
| EP3845638A4 (en) * | 2018-07-26 | 2022-05-11 | Kyoto University | METHOD OF PRODUCTION OF A CELL DELIVERED BY A RECEPTOR GENE OF A FOREIGN ANTIGEN |
| SG11202101284UA (en) | 2018-08-14 | 2021-03-30 | Sotio Llc | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof |
| KR20210125978A (ko) | 2018-11-01 | 2021-10-19 | 그라셀 바이오테크놀로지스 (상하이) 컴퍼니, 리미티드 | T 세포 조작을 위한 조성물 및 방법 |
| CN120005921A (zh) | 2018-12-12 | 2025-05-16 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
| EP3898946B1 (en) * | 2018-12-19 | 2023-02-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mucosal-associated invariant t (mait) cells expressing chimeric antigen receptors |
| KR20210125509A (ko) * | 2019-02-01 | 2021-10-18 | 케이에스큐 세러퓨틱스 인코포레이티드 | 개선된 면역요법을 위한 유전자-조절 조성물 및 방법 |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| CA3130489A1 (en) * | 2019-02-18 | 2020-08-27 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| US11969443B2 (en) | 2019-03-06 | 2024-04-30 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with self-driving chimeric antigen receptors |
| CA3130546A1 (en) | 2019-03-29 | 2020-10-08 | Tilman Schlothauer | Method for the generation of an fcrn expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| AU2020271523A1 (en) * | 2019-04-11 | 2021-10-14 | Fate Therapeutics, Inc. | CD3 reconstitution in engineered iPSC and immune effector cells |
| AU2020265749A1 (en) | 2019-05-01 | 2022-01-06 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods |
| CA3140064A1 (en) * | 2019-05-16 | 2020-11-19 | University Of Washington | Lockr-mediated recruitment of car t cells |
| WO2020254352A1 (en) * | 2019-06-19 | 2020-12-24 | F. Hoffmann-La Roche Ag | Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| JP7676358B2 (ja) | 2019-07-19 | 2025-05-14 | メモリアル スローン ケタリング キャンサー センター | 免疫療法のための融合ポリペプチド |
| US20220251572A1 (en) | 2019-07-23 | 2022-08-11 | Mnemo Therapeutics | Immune cells defective for suv39h1 |
| CN117925528A (zh) * | 2019-07-24 | 2024-04-26 | 浙江煦顼技术有限公司 | 具有增强记忆t细胞表型的修饰t细胞 |
| WO2021061832A1 (en) * | 2019-09-23 | 2021-04-01 | Regents Of The University Of Minnesota | Genetically-edited immune cells and methods of therapy |
| CN114765991A (zh) * | 2019-09-25 | 2022-07-19 | 小利兰·斯坦福大学董事会 | 非色素睫状上皮细胞特异性启动子 |
| SG10201909544YA (en) * | 2019-10-11 | 2021-05-28 | Nat Univ Singapore | Genetically Modified T Cells And Uses Thereof |
| TW202132560A (zh) * | 2019-11-13 | 2021-09-01 | 瑞士商Ｃｒｉｓｐｒ治療公司 | 製備car-t細胞之方法 |
| IL292329A (en) * | 2019-11-13 | 2022-06-01 | Crispr Therapeutics Ag | Manufacturing process for making t cells expressing chimeric antigen receptors |
| CN113122576A (zh) * | 2019-12-31 | 2021-07-16 | 博雅辑因（北京）生物科技有限公司 | 一种通用型truck-t细胞、其制备方法以及用途 |
| EP4084815A1 (en) * | 2020-01-02 | 2022-11-09 | Edity Therapeutics Ltd. | Delivery compositions and methods |
| CA3171369A1 (en) * | 2020-02-28 | 2021-09-02 | Wisconsin Alumni Research Foundation | Nonviral generation of genome edited chimeric antigen receptor t cells |
| JP2023518295A (ja) * | 2020-03-20 | 2023-04-28 | オルナ セラピューティクス インコーポレイテッド | 環状ｒｎａ組成物及び方法 |
| GB202006903D0 (en) * | 2020-05-11 | 2020-06-24 | Adaptimmune Ltd | Modified iPSCs |
| CN115867584A (zh) * | 2020-06-29 | 2023-03-28 | 细胞医学公司 | 用于减少嵌合抗原受体强直信号传导的方法和组合物 |
| WO2022011065A1 (en) * | 2020-07-07 | 2022-01-13 | The Nemours Foundation | Tumor-activated alloreactive and xenoreactive t cells and their use in immunotherapy against cancer |
| EP4188395A1 (en) | 2020-07-30 | 2023-06-07 | Institut Curie | Immune cells defective for socs1 |
| CN116323920A (zh) * | 2020-08-07 | 2023-06-23 | 荷兰商新基因治疗公司 | 富集基因工程t细胞的方法 |
| WO2022072712A1 (en) * | 2020-09-30 | 2022-04-07 | Vor Biopharma Inc. | Chimeric antigen receptor expression systems |
| JP2024501151A (ja) * | 2020-12-01 | 2024-01-11 | レプトン ファーマスーティカルズ リミテッド | 細胞療法のために単離された細胞の治療効率を高めるための方法 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| EP4019538A1 (en) | 2020-12-22 | 2022-06-29 | Charité - Universitätsmedizin Berlin | Reprogramming immune cells by targeted integration of zeta-deficient chimeric antigen receptor transgenes |
| CA3212964A1 (en) | 2021-03-11 | 2022-09-15 | Mnemo Therapeutics | Tumor neoantigenic peptides |
| CA3213004A1 (en) | 2021-03-11 | 2022-09-15 | Mnemo Therapeutics | Tumor neoantigenic peptides and uses thereof |
| MX2023010640A (es) | 2021-03-11 | 2024-02-07 | Inst Curie | Péptidos neoantigénicos transmembranales. |
| US20240271095A1 (en) * | 2021-05-14 | 2024-08-15 | Appia Bio, Inc. | Production of engineered t cells from stem cells |
| EP4413031A1 (en) | 2021-10-06 | 2024-08-14 | Miltenyi Biotec B.V. & Co. KG | Method for targeted gene insertion into immune cells |
| AU2022366817A1 (en) * | 2021-10-14 | 2024-05-02 | Appia Bio, Inc. | Engineering stem cell t cells with multiple t cell receptors |
| KR20240099259A (ko) | 2021-10-14 | 2024-06-28 | 아스널 바이오사이언시스, 인크. | 공동 발현된 shrna 및 논리 게이트 시스템을 갖는 면역 세포 |
| WO2023091783A1 (en) * | 2021-11-22 | 2023-05-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Engineered immune cells with reduced sirt6 expression |
| EP4456910A1 (en) | 2021-12-28 | 2024-11-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
| CN115304679B (zh) * | 2022-01-21 | 2024-07-16 | 郑州大学第一附属医院 | 一种促进t细胞分化的限制型car及其应用 |
| AU2023209589A1 (en) | 2022-01-21 | 2024-08-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Modulation of suv39h1 expression by rnas |
| WO2023178227A2 (en) * | 2022-03-17 | 2023-09-21 | University Of Florida Research Foundation, Incorporated | Chimeric lactate receptor engineered t cells |
| EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
| WO2023225670A2 (en) * | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
| EP4573114A2 (en) | 2022-08-19 | 2025-06-25 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ras mutations and uses thereof |
| WO2024050551A2 (en) * | 2022-09-02 | 2024-03-07 | Oncosenx, Inc. | Compositions and methods for in vivo expression of chimeric antigen receptors |
| BE1031219B1 (fr) | 2022-12-28 | 2024-07-29 | Quidditas Sa | Composition, cellules immunitaires la comprenant et utilisation de ces dernières |
| WO2025096594A2 (en) * | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof |
| WO2025096560A1 (en) * | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| WO2025163107A1 (en) | 2024-02-01 | 2025-08-07 | Institut Gustave Roussy | Immune cells defective for znf217 and uses thereof |
| WO2025213167A1 (en) * | 2024-04-05 | 2025-10-09 | Roswell Park Cancer Institute Corporation | Complement signaling as a t-cell checkpoint in the tumor microenvironment (tme) |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| AU2002246733B2 (en) | 2000-12-19 | 2007-09-20 | Altor Bioscience Corporation | Transgenic animals comprising a humanized immune system |
| DE60106469T2 (de) | 2001-12-22 | 2005-10-13 | 4-Antbody AG | Verfahren zur Herstellung von genetisch veränderten Lymphozyten Vorläuferzellen von Wirbeltieren und deren Gebrauch zur Produktion von heterologen Bindeproteinen |
| JP4238138B2 (ja) | 2001-12-22 | 2009-03-11 | ４−アンチボディ アーゲー | 遺伝的に修飾された脊椎動物前駆体リンパ球の生成方法及び異種結合タンパク質の産生を目的としたその使用。 |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2005026718A1 (en) | 2003-08-28 | 2005-03-24 | Five Prime Therapeutics, Inc. | Stem cell libraries |
| US20110213288A1 (en) | 2007-04-23 | 2011-09-01 | The Board Of Regents, The University Of Texas System | Device And Method For Transfecting Cells For Therapeutic Uses |
| KR101363928B1 (ko) | 2007-06-11 | 2014-02-19 | 고쿠리츠다이가쿠호진 미에다이가쿠 | 특이적 유전자 발현 방법 |
| JP5681114B2 (ja) * | 2008-12-04 | 2015-03-04 | サンガモ バイオサイエンシーズ， インコーポレイテッド | 亜鉛フィンガーヌクレアーゼを使用したラットのゲノム編集 |
| AU2010275432A1 (en) | 2009-07-24 | 2012-02-02 | Sigma-Aldrich Co. Llc. | Method for genome editing |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| ES2717629T3 (es) | 2009-11-03 | 2019-06-24 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas |
| US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| CA2993567C (en) | 2010-07-21 | 2022-06-28 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a t-cell receptor gene |
| PH12013502531A1 (en) | 2011-08-23 | 2014-01-20 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| ES2828663T3 (es) | 2012-04-18 | 2021-05-27 | Univ Leland Stanford Junior | Dirección genética no disruptiva |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| PL4289948T3 (pl) | 2012-05-25 | 2025-06-02 | The Regents Of The University Of California | Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji |
| AU2013329186B2 (en) * | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| PT3613439T (pt) | 2013-02-15 | 2021-05-12 | Univ California | Recetor de antigénio quimérico e métodos de utilização do mesmo |
| US9499855B2 (en) * | 2013-03-14 | 2016-11-22 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
| WO2014153470A2 (en) | 2013-03-21 | 2014-09-25 | Sangamo Biosciences, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
| EP3789487A1 (en) | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| EP2986636B1 (en) | 2013-04-17 | 2018-11-14 | Baylor College Of Medicine | Immunosuppressive tgf-beta signal converter |
| EP2997134B1 (en) | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| US9890393B2 (en) | 2013-05-29 | 2018-02-13 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system |
| AU2015233347A1 (en) | 2014-03-21 | 2016-09-08 | Cellectis | Engineering mammalian genome using DNA-guided Argonaute interference systems (DAIS) |
| CA2945393C (en) * | 2014-04-24 | 2021-03-23 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| CA2948614A1 (en) | 2014-05-09 | 2015-11-12 | Research Foundation Of The City University Of New York | Tcr(alpha)-lcr-derived gene regulatory cassettes |
| EP3152319A4 (en) * | 2014-06-05 | 2017-12-27 | Sangamo BioSciences, Inc. | Methods and compositions for nuclease design |
| HUE049776T2 (hu) | 2014-06-06 | 2020-10-28 | Regeneron Pharma | Módszerek és készítmények egy célzott lókusz módosítására |
| WO2016044745A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| US11319555B2 (en) | 2014-11-20 | 2022-05-03 | Duke University | Compositions, systems and methods for cell therapy |
| CN115537396A (zh) | 2015-03-27 | 2022-12-30 | 哈佛学院校长同事会 | 经过修饰的t细胞及其制备和使用方法 |
| WO2016166268A1 (en) | 2015-04-17 | 2016-10-20 | Cellectis | Engineering animal or plant genome using dna-guided argonaute interference systems (dais) from mesophilic prokaryotes |
| US10322774B2 (en) * | 2015-05-15 | 2019-06-18 | Oru Designs, Llc | Collapsible kayak with large cockpit |
| AU2016291778B2 (en) * | 2015-07-13 | 2021-05-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| IL295616A (en) | 2015-07-31 | 2022-10-01 | Us Health | Adapted cells and treatment methods |
| DK3359184T3 (da) * | 2015-10-05 | 2020-06-15 | Prec Biosciences Inc | Genetisk modificerede celler, der omfatter et modificeret gen fra konstant alfaregion i human t-cellereceptor |
| DK3359660T3 (en) | 2015-10-05 | 2020-02-17 | Prec Biosciences Inc | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| SG11201803145RA (en) | 2015-11-04 | 2018-05-30 | Fate Therapeutics Inc | Methods and compositions for inducing hematopoietic cell differentiation |
| AU2016349504B2 (en) | 2015-11-04 | 2023-02-09 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| US20210206826A1 (en) | 2015-11-19 | 2021-07-08 | The Regents Of The University Of California | Conditionally repressible immune cell receptors and methods of use thereof |
| RU2018135819A (ru) | 2016-03-11 | 2020-04-13 | Блубёрд Био, Инк. | Иммунные эффекторные клетки с отредактированным геномом |
| SG11201807286WA (en) | 2016-03-19 | 2018-10-30 | F1 Oncology Inc | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
| CA3020330A1 (en) | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
| SG11201808831TA (en) | 2016-04-15 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
-
2017
- 2017-04-14 SG SG11201808831TA patent/SG11201808831TA/en unknown
- 2017-04-14 CN CN201780037351.1A patent/CN109790517B/zh active Active
- 2017-04-14 KR KR1020227029151A patent/KR102614675B1/ko active Active
- 2017-04-14 AU AU2017250769A patent/AU2017250769B2/en active Active
- 2017-04-14 BR BR112018071199-3A patent/BR112018071199A2/pt active Search and Examination
- 2017-04-14 KR KR1020237042980A patent/KR20240000616A/ko active Pending
- 2017-04-14 EP EP17735670.6A patent/EP3443075B1/en active Active
- 2017-04-14 EP EP22197444.7A patent/EP4180519B1/en active Active
- 2017-04-14 ES ES22197444T patent/ES3039670T3/es active Active
- 2017-04-14 JP JP2018554069A patent/JP7058223B2/ja active Active
- 2017-04-14 ES ES17735670T patent/ES2933961T3/es active Active
- 2017-04-14 PT PT221974447T patent/PT4180519T/pt unknown
- 2017-04-14 PT PT177356706T patent/PT3443075T/pt unknown
- 2017-04-14 EP EP25181439.8A patent/EP4628587A3/en active Pending
- 2017-04-14 WO PCT/US2017/027601 patent/WO2017180989A2/en not_active Ceased
- 2017-04-14 KR KR1020187032919A patent/KR102437015B1/ko active Active
- 2017-04-14 US US16/091,494 patent/US11377637B2/en active Active
-
2022
- 2022-05-25 US US17/824,650 patent/US12404316B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511236A5 (enExample) | ||
| KR102691932B1 (ko) | 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포 | |
| US11981721B2 (en) | Transposon-based transfection system for primary cells | |
| KR102495308B1 (ko) | 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터 | |
| JP7005346B2 (ja) | 養子細胞免疫療法の有効性を増強させるための組成物および方法 | |
| JP6161098B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| IL274179B2 (en) | Targeted replacement of endogenous T cell receptors | |
| Gowrishankar et al. | Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells | |
| ES3041600T3 (en) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogennous foxp3 gene | |
| KR20200015939A (ko) | 신규의 세포 태그의 발현 | |
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| CN109415687A (zh) | 嵌合抗原受体t细胞组合物 | |
| KR20170108946A (ko) | Fc 수용체-유사 5를 표적화하는 키메라 항원 수용체 및 그의 용도 | |
| Campillo-Davo et al. | Efficient and non-genotoxic RNA-based engineering of human T cells using tumor-specific T cell receptors with minimal TCR mispairing | |
| CA2978171A1 (en) | T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof | |
| CN106535925A (zh) | 基于car的免疫治疗 | |
| JP2021518747A (ja) | Ｒｎａ不安定化エレメントを使用した遺伝子発現の調整 | |
| Middelburg et al. | The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent | |
| US20230279352A1 (en) | Methods for generating primary immune cells | |
| JP6723164B2 (ja) | Ｔ細胞集団の改変方法 | |
| KR20200129959A (ko) | 무-운반체 다중 CRISPR/Cas 9 유전자 편집 복합체 및 그의 용도 | |
| WO2010114129A1 (ja) | Ｔ細胞レセプター及び該レセプターをコードする核酸 | |
| US20250270546A1 (en) | Guide rnas and uses thereof | |
| Hoseini et al. | Inducible T-cell receptor expression in precursor T cells for leukemia control | |
| Yang et al. | Analysis of the complex genomic structure of Bcl-x and its relationship to Bcl-xγ expression after CD28-dependent costimulation |